perpetuity. medRxiv preprint doi: https://doi.org/10.1101/2023.10.31.23297819; this version posted October 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted :opyright holder for this



- 11 of North Carolina at Chapel Hill, Chapel Hill, NC, United States
- 12 <sup>2</sup> Department of Epidemiology, School of Public Health, Guangdong Provincial Key Laboratory of
- 13 Tropical Disease Research, Southern Medical University, Guangzhou, China
- 14 <sup>3</sup>Department of Epidemiology, Gillings School of Global Public Health, Chapel Hill, NC, United
- 15 States

3

5

9

- 16 <sup>4</sup>Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo
- <sup>5</sup>17 SANRU Asbl, Kinshasa, Democratic Republic of the Congo
- 18 <sup>6</sup>Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania
- 19
- 20 \* Corresponding author
- 21 E-mail: [jonathan\\_parr@med.unc.edu](mailto:jonathan_parr@med.unc.edu) (JBP) **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

# **Abstract**

#### **Background**

 *P. ovale* spp. infections are endemic across multiple African countries and are caused by two distinct non-recombining species, *P. ovale curtisi* (*Poc*) and *P. ovale wallikeri* (*Pow*). These species are thought to differ in clinical symptomatology and latency, but existing diagnostic assays have limited ability to detect and distinguish them. In this study, we developed a new duplex assay for the detection and differentiation of *Poc* and *Pow* that can be used to improve our understanding of these parasites.

#### **Methods**

 Repetitive sequence motifs were identified in available *Poc* and *Pow* genomes and used for assay development and validation. We evaluated the analytical sensitivity and specificity of the best-performing assay using a panel of samples from Tanzania and the Democratic Republic of the Congo (DRC), then validated its performance using 55 *P. ovale* spp. samples and 40 non-ovale *Plasmodium* samples from the DRC. *Poc* and *Pow* prevalence among symptomatic individuals sampled across three provinces of the DRC were estimated.

#### **Results**

 The best-performing *Poc* and *Pow* targets had 9 and 8 copies within the reference genomes, respectively. Our duplex assay had 100% specificity and 95% confidence lower limits of detection of 4.2 and 41.2 parasite genome equivalents/µl for *Poc* and

 *Pow*, respectively. Species was determined in 80% of all *P. ovale* spp.-positive field samples and 100% of those with >10 parasites/µl. Most *P. ovale* spp. field samples from the DRC were found to be *Poc* infections.

**Conclusions**

 We identified promising multi-copy targets for molecular detection and differentiation of *Poc* and *Pow* and used them to develop a new duplex real-time PCR assay that performed well when applied to diverse field samples. Though low-density *Pow* infections are not reliably detected, the assay is highly specific and can be used for high-throughput studies of *P. ovale* spp. epidemiology among symptomatic cases in malaria-endemic countries like the DRC.

**Keywords:** *P. ovale curtisi*; *P. ovale wallikeri*; qualitative real-time PCR; prevalence;

Congo; non-falciparum malaria

#### **Author Summary**

 Non-falciparum malaria is gaining attention, especially in settings where *P. falciparum*  transmission is declining. *Plasmodium ovale curtisi* (*Poc*) and *wallikeri* (*Pow*) are neglected parasites that can cause relapsing malaria and are thought to differ in clinical symptomatology and latency. However, existing diagnostic assays have limited ability to detect and distinguish *Poc* and *Pow* and are not well-suited for high-throughput use, hindering our understanding of *P. ovale* spp. epidemiology. Mining recently available *Poc* and *Pow* reference genomes, we identify new multi-copy targets for molecular detection and develop a novel duplex qualitative real-time PCR assay capable of species



# **Introduction**

 Malaria remains a major global health concern despite decades of sustained investment in elimination efforts. Though most malaria programs prioritize *Plasmodium falciparum*, the parasite species responsible for most deaths, increasing evidence confirms co-circulation of other neglected *Plasmodium* species that cause human malaria [1]. Recent surveys reveal a previously unappreciated burden of *Plasmodium ovale* spp. in multiple African countries [2, 3], where relapsing malaria caused by *P. ovale* spp. may prove to be an obstacle to malaria elimination efforts [4- 6]. *P. ovale* comprises two distinct non-recombining species, *P. ovale curtisi* (*Poc*) and *P. ovale wallikeri* (*Pow*) [7]. *Poc* and *Pow* have potential differences in clinical symptomatology and latency [8], but existing diagnostic assays have limited ability to detect and distinguish them, and require multiple steps or prolonged cycling time that increases risk of false-positive results [9].

 Detection and differentiation of *Poc* and *Pow* is not currently possible using conventional malaria diagnostic assays relying on microscopy. Microscopic examination of blood smears remains the gold standard for malaria diagnosis, but differentiation of parasite species and examination of low parasite density or mixed- species infections is challenging and requires significant expertise [10]. *Poc* and *Pow*  infections often occur as mixed infections at low density, and are morphologically indistinguishable on blood slides [11, 12]. Furthermore, widely used malaria rapid diagnostic tests (RDTs) fail to detect samples with low parasite densities and cannot

distinguish parasite species other than *P. falciparum* and *Plasmodium vivax* [13, 14].

Thus, alternative methods are required to identify these neglected species.



# **Materials and Methods**

### **Mining and selection of multi-copy targets in** *P. ovale curtisi*

### **and** *P. ovale wallikeri* **genomes**



 **Fig 1. Approach to developing a real-time PCR assay for detection and differentiation of** *P. ovale curtisi* **and** *P. ovale wallikeri***.**

#### **Assay development and optimization**

A panel of 15 well-characterized *Poc* and *Pow* field samples and six non-ovale

 *Plasmodium* laboratory controls were selected for assay development and analytical specificity analysis. Field samples included 11 *Poc* and four *Pow* leukodepleted blood samples and dried blood spot (DBS) samples from Tanzania and the Democratic Republic of the Congo (DRC). Laboratory controls included two *P. falciparum*, one *P. malariae*, two *P. vivax*, and one *P. knowlesi* samples from an external quality assurance program [22]. DNA was extracted from dried blood spot (DBS) and leukodepleted blood samples using Chelex 100 (Bio-Rad, Fishers, Indiana, USA) [23] and the QIAamp DNA Mini Kit (Qiagen, Mettmann, North Rhine-Westphalia, Germany), respectively. *P. ovale* parasite densities were estimated using a semi-quantitative real- time PCR assay targeting the 18S rRNA gene of both *P. ovale* spp. as previously described [2]. *Poc* versus *Pow* species was determined using two singleplex real-time PCR assays as previously described [9].

 Primer sets with the best specificity for *Poc* and *Pow* versus this panel of samples were selected. A duplex qualitative real-time PCR assay was developed based on the selected primer sets and the corresponding probes. Assay optimization was then performed using synthetic plasmids containing targets for *Poc* and *Pow* detection (Azenta Life Sciences, Indianapolis, Indiana, USA). We tested a range of annealing temperatures and of primer and probe concentrations to identify optimal reaction conditions. All optimization analyses were performed in duplicate.

#### **Analytical sensitivity and specificity**



# **Validation using field samples**

 The assay's clinical sensitivity and specificity were assessed using 95 dried blood spot samples selected from a large sample set from a previous study conducted in the DRC [25], including 55 *P. ovale* spp. samples and 40 non-ovale *Plasmodium* samples (20 *P. falciparum* infections, 10 *P. malariae* infections, and 10 *P. falciparum* and *P. malariae* mixed infections) [25]. DNA was extracted using Chelex 100 as described above. *Plasmodium species* and parasite densities were identified using real-time PCR assays for *P. ovale*, *P. falciparum* and *P. malariae* as previously described, with samples positive in duplicate selected for use during validation of the present assay, and the previously published singleplex real-time PCR assay for both *P. ovale* spp. used as the gold standard for clinical sensitivity and specificity calculations [2, 26, 27]. Samples with Ct values lower than 45 in duplicate by our new assay were considered to be positive.

#### It is made available under a CC-BY 4.0 International license.

# **Epidemiology of** *Poc* **and** *Pow* **among symptomatic patients in the DRC**

 We investigated the epidemiology of *P. ovale* spp. infection and the distribution of *Poc* vs *Pow* infections using samples from a study of symptomatic malaria across three provinces in the DRC. Among a randomly selected group of 1,000 symptomatic individuals, 64 samples were previously found be positive for *P. ovale* spp. by real-time 176 PCR testing [2, 25]. The  $\chi^2$  test or Fisher's exact test was used for comparison with categorical variables that might be associated with *P. ovale* spp.-infections based on results of previously published studies [28-33], including age, sex, *P. falciparum* co- infection, bed net use, education level, recurrent malaria infection (any prior *Plasmodium* species infections within 6 months), and rural residence. Though no significant association between pregnancy and malaria was reported in previous studies, pregnancy was included in the present analysis.

 We calculated crude odds ratios (cORs) and their 95% confidence intervals (CI) to evaluate associations between each of these eight factors and *P. ovale* infections. Because DNA degradation is possible during long-term storage, we repeated the previously published singleplex *P. ovale* spp. real-time PCR assay on the 64 samples previously identified as *P. ovale* spp.-positive. Among these, 44 tested positive in duplicate and were selected for species determination using the present duplex assay. To determine the proportions of *Poc* and *Pow* within these *P. ovale* spp.-positive samples, inverse probability weighting (IPW) was used to account for differences

 between selected samples and the original 64 *P. ovale* spp.-positive samples. Selection weights were calculated by multiple logistic regression analysis with the following covariates: gender, age, area, and *P. ovale* spp. parasitemia.

#### **Statistical analysis**

 Statistical analysis was performed using R software (version 4.2.0; R Core Team, Vienna, Austria) in RStudio (version 2022.02.2). Figures were generated using the *ggplot2* (version 3.4.1) and *forestplot* (version 3.1.1) packages. Mapping was done via

pixelmap [34].

#### **Ethical approvals**

 Existing samples from previous studies were chosen based on convenience. DRC samples were collected as part of a 2017 study investigating malaria diagnostic test performance in three provinces, Kinshasa, Bas-Uele, and Sud-Kivu[25]. Tanzania samples were collected from participants enrolled in a malaria transmission study in rural Bagamoyo district from 2018-2019 [9, 35, 36]. Enrolled subjects provided informed consent or assent. Ethical approvals for these studies were obtained from the Kinshasa School of Public Health, Muhimbili University of Health and Allied Sciences, and the University of North Carolina at Chapel Hill.

#### **Results**

#### *P. ovale curtisi* **and** *P. ovale wallikeri* **target selection and assay**

#### **development**

![](_page_11_Picture_321.jpeg)

 Combining these *Poc* and *Pow* primers and probes, we optimized a duplex, qualitative real-time PCR assay for the detection and differentiation for *Poc* and *Pow*. 228 The final, optimized duplex assay was performed in a small final volume of  $10\mu$ l, 229 including 7µl of reaction master-mix containing 2x FastStart Universal Probe Master (Rox) (Roche, Basel, Switzerland), primers and probes (240 nM of Poc\_Fwd, 240 nM of Poc\_Rev, 60 nM of Poc\_Probe, 800 nM of Pow\_Fwd, 800 nM of Pow\_Rev, 320nM

#### 232 of Pow Probe); and 3µl of DNA template. Optimal thermocycling conditions were two

- 233 min at 50°C, 10 min at 95°C, followed by 45 cycles of 15 s at 95°C and 60 s at 58°C,
- 234 allowing for detection of parasite DNA in less than two hours.

#### 235 **Table 1**. **Best performing primers and probes for** *P. ovale curtisi* **and** *P. ovale*

#### 236 *wallikeri* **detection**

![](_page_12_Picture_213.jpeg)

#### 237 **Analytical sensitivity and specificity**

 The 95% confidence lower limits of detection for *Poc* and *Pow* were 4.2 and 41.2 parasite genome equivalents/µl, respectively (Fig 2A, S1 Fig and S2 Table). All well- characterized *Poc* and *Pow* field samples were successfully detected and differentiated with no cross-reactivity between species, and no cross reactivity was found in six non- ovale *Plasmodium* controls (Fig 2B), consistent with 100% analytical specificity. 243

244 **Fig 2. Duplex** *Poc* **and** *Pow* **assay performance. A)** Analytical sensitivity when

 applied to multiple replicates of serially diluted plasmid DNA (n=104 and 161 total replicates for *Poc* and *Pow*, respectively). Points are colored to display target detection (blue) versus no detection (red). The 95% lower limit of detection (LOD) determined using probit analysis is shown for each species. **B)** Analytical specificity versus genomic DNA extracted from a panel of well-characterized leukodepleted blood (LDB) and dried blood spot (DBS) samples from Tanzania and the DRC with *Poc* and *Pow*  confirmed by nested PCR, and non-ovale *Plasmodium* samples from an external quality assurance program. All *Poc* and *Pow* samples were correctly identified, and no false-positives were observed among other *Plasmodium* species.

#### **Validation using field samples**

 The assay demonstrated excellent clinical sensitivity at higher parasite densities and perfect specificity when applied to 95 field samples collected in the DRC. Parasite densities of 55 *P. ovale* spp.-positive field samples included in this study ranged from 258 0.9 parasites/ $\mu$ l to 2,468 parasites/ $\mu$ l; 29 (52.7%) had parasite densities <10 parasites/ $\mu$ l. The assay's overall sensitivity was 80%, successfully determining *P. ovale* species in 44 of the *P. ovale* spp.-positive field samples (Fig 3A); however, assay sensitivity was 261 100% for infections with  $>10$  parasites/ $\mu$ l. The lowest parasite densities in which species could be determined were 2.0 and 20.9 parasites/µl for *Poc* and *Pow*, respectively. None of the 40 non-ovale *Plasmodium* field samples were detected by the duplex assay, consistent with 100% specificity (Fig 3B).

![](_page_14_Picture_208.jpeg)

# **Epidemiology of symptomatic malaria due to** *P. ovale* **in the DRC**

 A total of 64 *P. ovale* spp.-positive samples were previously identified among randomly selected field samples from 1,000 participants in three provinces in the DRC [25]. The prevalences of *P. ovale* spp.-infection in Bas-Uele, Kinshasa, and Sud-Kivu were 14.3% (47/328), 2.8% (10/353), and 2.2% (7/319), respectively. Among these 1,000 participants, urban residence (cOR: 0.31, 0.17-0.55) and bed net use (cOR: 0.50, 0.24-0.85) had significant protective associations with *P. ovale* spp. infection; while recurrent malaria infection (within 6 months) (cOR: 1.75, 1.02-3.03) and coinfection

 with *P. falciparum* (cOR: 7.70, 3.48-17.06) was associated with *P. ovale* spp. infection (Fig 4).

 **Fig 4. Factors associated with** *P. ovale* **spp. (comprising both** *Poc* **and** *Pow***) infections.** Crude odds ratio estimates and associated 95% confidence intervals are displayed.

 Among the subsample of 44 *P. ovale* spp.-positive samples selected for species determination, *P. ovale* species was determined in 37 (84%) samples using the present assay: 28 (75.7%), 6 (16.2%), and 3 (8.1%) were *Poc* infections, *Pow* infections, and *Poc*-*Pow* mixed infections, respectively. Inverse probability weighting analysis indicated that 89.8% of all *P. ovale* spp. infections in our cohort included *Poc* species, alone or as a *Poc*-*Pow* mixed infection, and 15.2% included *Pow* species, alone or as a *Poc*-*Pow* mixed infection.

#### **Discussion**

 We mined recently published genomes of *Poc* and *Pow* to develop a highly specific duplex real-time PCR assay that can be used to improve our understanding of their epidemiology in malaria-endemic countries. Recent studies have revealed a previously

![](_page_16_Picture_237.jpeg)

such as *lsa3* might be important in human infection [41-44]. We leveraged the repetitive

nature of these poorly understood *Poc* and *Pow* targets to develop an assay with several

advantageous performance characteristics.

![](_page_17_Picture_268.jpeg)

 The prevalence of *P. ovale* infections in symptomatic individuals from the published study was 6.4% [25], while lower prevalence of *P. ovale* infections were found in nationally representative, asymptomatic adults (0.5%) and children (4.7%) in

![](_page_18_Picture_270.jpeg)

 Several limitations of our approach should be highlighted. First, the assay's relatively low sensitivity at lower parasite densities, particularly for *Pow* detection, limits its utility in low-density or asymptomatic infections. Thus, the prevalence of *Poc*  and particularly *Pow* in our study are likely underestimated. This limitation could be overcome in the future by combining a pan-*P. ovale* spp. 18S rRNA assay (e.g. such as that used by Mitchell et al. [2]) with our *Poc lsa3* assay, allowing definitive identification of *Poc* (pan-*P. ovale* spp.-positive, *Poc lsa3-*positive) and deductive identification of *Pow* mono-infection (pan-*P. ovale* spp.-positive, *Poc lsa3-*negative).

 Second, our *Poc* and *Pow* prevalence estimates are derived from people presenting with malaria symptoms to health facilities in three DRC provinces. The DRC is a large and diverse country. Our results provide further insight into the epidemiology of *Poc* and *Pow* in three large regions but do not provide precise, nationally representative estimates, nor information about asymptomatic infections. Third, crude associations were analyzed in this study to explore possible factors related to *P. ovale*; no causal relationships were assessed. Fourth, the assay targets two non-essential genomic regions at risk of deletion or disruption if future treatment choices are tied to diagnosis, as has been proposed for *P. falciparum* and observed for *Chlamydia trachomatis* non- essential diagnostic targets [52, 53]. However, this hypothetical threat is unlikely to be realized any time soon. Malaria programs in Africa focus largely on *P. falciparum* and do not routinely offer radical cure to clear *P. ovale* spp. hypnozoites. In conclusion, we developed and validated a novel, highly specific duplex real-

 time PCR assay capable of detection and differentiation of *Poc* and *Pow*. Though our assay's sensitivity at lower parasite densities could be further improved, its streamlined work-flow reduces complexity and is well suited for high-throughput use in field studies. As some countries progress toward malaria elimination, improved assays for *Poc* and *Pow* like that presented here will become more important and open the way to improved understanding of *P. ovale* spp. epidemiology, clinical impact, to inform eradication strategies.

# **Acknowledgements**

![](_page_20_Picture_142.jpeg)

# **Author contributions**

 J.B.P. and W.H. conceptualized the study. J.B.P., J.J.J., J.T.L., and W.H. designed experiments. M.K., A.T., F.P., A.K., and B.N. collected field samples. W.H., V.R.P., K.L.T., and R.S. performed laboratory and epidemiological analyses. W.H. prepared the figures and wrote the first draft. All authors reviewed and approved the final draft. 

#### **Funding**

 This study was funded by the US National Institutes of Health (NIH R21AI148579 to JBP and JTL). It was partly supported by the Global Fund to Fight AIDS, Tuberculosis, and Malaria (MK, AT, FP, AK; DRC sample collection); NIH R01AI137395 (JTL and BN; Tanzania sample collection), K24AI134990 (JJJ), and T32AI070114 (RS).

# **Competing interests**

- JBP reports research support from Gilead Sciences, non-financial support from
- Abbott Laboratories, and consulting for Zymeron Corporation, all outside the scope of
- the manuscript. All other authors declare no competing interests.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.31.23297819;](https://doi.org/10.1101/2023.10.31.23297819) this version posted October 31, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted

#### It is made available under a CC-BY 4.0 International license.

#### **References**

- 1. Talapko J, Škrlec I, Alebić T, Jukić M, Včev A. Malaria: The Past and the Present. Microorganisms. 2019;7(6). Epub 2019/06/27. doi: 10.3390/microorganisms7060179. PubMed PMID: 31234443; PubMed Central PMCID: PMC6617065.
- 2. Mitchell CL, Brazeau NF, Keeler C, Mwandagalirwa MK, Tshefu AK, Juliano JJ, et al. Under the Radar: Epidemiology of Plasmodium ovale in the Democratic Republic of the Congo. The Journal of infectious diseases. 2021;223(6):1005-14. Epub 2020/08/09. doi: 10.1093/infdis/jiaa478. PubMed PMID: 32766832; PubMed Central PMCID: PMC8006425.
- 3. Bredu D, Donu D, Amoah LE. Dynamics of the Composition of Plasmodium Species Contained within Asymptomatic Malaria Infections in the Central Region of Ghana. Journal of tropical medicine. 2021;2021:7419548. Epub 2021/03/18. doi: 10.1155/2021/7419548. PubMed PMID: 33727937; PubMed Central PMCID: PMC7936885.
- 4. Merrick CJ. Hypnozoites in Plasmodium: Do Parasites Parallel Plants? Trends in parasitology. 2021;37(4):273-82. Epub 2020/12/02. doi: 10.1016/j.pt.2020.11.001. PubMed PMID: 33257270.
- 5. Wångdahl A, Sondén K, Wyss K, Stenström C, Björklund D, Zhang J, et al. Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022;74(7):1199-207. Epub 2021/07/04. doi: 10.1093/cid/ciab610. PubMed PMID: 34216464; PubMed Central PMCID: PMC8994585.
- 6. Lover AA, Baird JK, Gosling R, Price RN. Malaria Elimination: Time to Target All Species. The American journal of tropical medicine and hygiene. 2018;99(1):17-23. Epub 2018/05/16. doi: 10.4269/ajtmh.17-0869. PubMed PMID: 29761762; PubMed Central PMCID: PMC6035869.
- 7. Sutherland CJ, Tanomsing N, Nolder D, Oguike M, Jennison C, Pukrittayakamee S, et al. Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. The Journal of infectious diseases. 2010;201(10):1544-50. Epub 2010/04/13. doi: 10.1086/652240. PubMed PMID: 20380562.
- 8. Joste V, Bailly J, Hubert V, Pauc C, Gendrot M, Guillochon E, et al. Plasmodium ovale wallikeri and P. ovale curtisi Infections and Diagnostic Approaches to Imported Malaria, France, 2013-2018. Emerging infectious diseases. 2021;27(2):372-84. Epub 2021/01/27. doi: 10.3201/eid2702.202143. PubMed

PMID: 33496652; PubMed Central PMCID: PMC7853592.

 9. Potlapalli V, Muller MS, Ngasala B, Ali IM, Na YB, Williams DR, et al. Real-time PCR detection of mixed Plasmodium ovale curtisi and wallikeri species infections in human and mosquito hosts. bioRxiv : the preprint server for biology. 2023. Epub 2023/04/11. doi: 10.1101/2023.03.31.535020. PubMed PMID: 37034766; PubMed Central PMCID: PMC10081274.

 10. Oyegoke OO, Maharaj L, Akoniyon OP, Kwoji I, Roux AT, Adewumi TS, et al. Malaria diagnostic methods with the elimination goal in view. Parasitology research. 2022;121(7):1867-85. Epub 2022/04/24. doi: 10.1007/s00436-022-07512-9. PubMed PMID: 35460369; PubMed Central PMCID: PMC9033523.

 11. Hawadak J, Dongang Nana RR, Singh V. Epidemiological, Physiological and Diagnostic Comparison of Plasmodium ovale curtisi and Plasmodium ovale wallikeri. Diagnostics (Basel, Switzerland). 2021;11(10). Epub 2021/10/24. doi: 10.3390/diagnostics11101900. PubMed PMID: 34679597; PubMed Central PMCID: PMC8534334.

 12. Kotepui M, Masangkay FR, Kotepui KU, De Jesus Milanez G. Misidentification of Plasmodium ovale as Plasmodium vivax malaria by a microscopic method: a meta- analysis of confirmed P. ovale cases. Scientific reports. 2020;10(1):21807. Epub 2020/12/15. doi: 10.1038/s41598-020-78691-7. PubMed PMID: 33311528; PubMed Central PMCID: PMC7733466.

 13. Mouatcho JC, Goldring JPD. Malaria rapid diagnostic tests: challenges and prospects. Journal of medical microbiology. 2013;62(Pt 10):1491-505. Epub 2013/09/21. doi: 10.1099/jmm.0.052506-0. PubMed PMID: 24048274.

 14. Mukkala AN, Kwan J, Lau R, Harris D, Kain D, Boggild AK. An Update on Malaria Rapid Diagnostic Tests. Current infectious disease reports. 2018;20(12):49. Epub 2018/10/26. doi: 10.1007/s11908-018-0655-4. PubMed PMID: 30353400.

 15. Oguike MC, Betson M, Burke M, Nolder D, Stothard JR, Kleinschmidt I, et al. Plasmodium ovale curtisi and Plasmodium ovale wallikeri circulate simultaneously in African communities. International journal for parasitology. 2011;41(6):677-83. Epub 2011/02/15. doi: 10.1016/j.ijpara.2011.01.004. PubMed PMID: 21315074; PubMed Central PMCID: PMC3084460.

 16. Tanomsing N, Imwong M, Sutherland CJ, Dolecek C, Hien TT, Nosten F, et al. Genetic marker suitable for identification and genotyping of Plasmodium ovale curtisi and Plasmodium ovale wallikeri. Journal of clinical microbiology. 2013;51(12):4213-6. Epub 2013/09/27. doi: 10.1128/jcm.01527-13. PubMed PMID: 24068009; PubMed Central PMCID: PMC3838052.

17. Perandin F, Manca N, Calderaro A, Piccolo G, Galati L, Ricci L, et al. Development

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.31.23297819;](https://doi.org/10.1101/2023.10.31.23297819) this version posted October 31, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a CC-BY 4.0 International license.

 of a real-time PCR assay for detection of Plasmodium falciparum, Plasmodium vivax, and Plasmodium ovale for routine clinical diagnosis. Journal of clinical microbiology. 2004;42(3):1214-9. Epub 2004/03/09. doi: 10.1128/jcm.42.3.1214- 1219.2004. PubMed PMID: 15004078; PubMed Central PMCID: PMC356834.

- 18. Calderaro A, Piccolo G, Gorrini C, Montecchini S, Rossi S, Medici MC, et al. A new real-time PCR for the detection of Plasmodium ovale wallikeri. PloS one. 2012;7(10):e48033. Epub 2012/10/31. doi: 10.1371/journal.pone.0048033. PubMed PMID: 23110165; PubMed Central PMCID: PMC3480495.
- 19. Rutledge GG, Böhme U, Sanders M, Reid AJ, Cotton JA, Maiga-Ascofare O, et al. Plasmodium malariae and P. ovale genomes provide insights into malaria parasite evolution. Nature. 2017;542(7639):101-4. Epub 2017/01/25. doi: 10.1038/nature21038. PubMed PMID: 28117441; PubMed Central PMCID: PMC5326575.
- 20. Marçais G, Kingsford C. A fast, lock-free approach for efficient parallel counting of occurrences of k-mers. Bioinformatics (Oxford, England). 2011;27(6):764-70. Epub 2011/01/11. doi: 10.1093/bioinformatics/btr011. PubMed PMID: 21217122; PubMed Central PMCID: PMC3051319.
- 21. Kibbe WA. OligoCalc: an online oligonucleotide properties calculator. Nucleic acids research. 2007;35(Web Server issue):W43-6. Epub 2007/04/25. doi: 10.1093/nar/gkm234. PubMed PMID: 17452344; PubMed Central PMCID: PMC1933198.
- 22. Cunningham JA, Thomson RM, Murphy SC, de la Paz Ade M, Ding XC, Incardona S, et al. WHO malaria nucleic acid amplification test external quality assessment scheme: results of distribution programmes one to three. Malaria journal. 2020;19(1):129. Epub 2020/04/02. doi: 10.1186/s12936-020-03200-0. PubMed PMID: 32228615; PubMed Central PMCID: PMC7106789.
- 23. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. The American journal of tropical medicine and hygiene. 1995;52(6):565-8. Epub 1995/06/01. doi: 10.4269/ajtmh.1995.52.565. PubMed PMID: 7611566.
- 24. Cunningham CH, Hennelly CM, Lin JT, Ubalee R, Boyce RM, Mulogo EM, et al. A novel CRISPR-based malaria diagnostic capable of Plasmodium detection, species differentiation, and drug-resistance genotyping. EBioMedicine. 2021;68:103415. Epub 2021/06/18. doi: 10.1016/j.ebiom.2021.103415. PubMed PMID: 34139428; PubMed Central PMCID: PMC8213918.
- 25. Parr JB, Kieto E, Phanzu F, Mansiangi P, Mwandagalirwa K, Mvuama N, et al. Analysis of false-negative rapid diagnostic tests for symptomatic malaria in the

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.31.23297819;](https://doi.org/10.1101/2023.10.31.23297819) this version posted October 31, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a CC-BY 4.0 International license.

 Democratic Republic of the Congo. Scientific reports. 2021;11(1):6495. Epub 2021/03/24. doi: 10.1038/s41598-021-85913-z. PubMed PMID: 33753817; PubMed Central PMCID: PMC7985209.

- 26. Veron V, Simon S, Carme B. Multiplex real-time PCR detection of P. falciparum, P. vivax and P. malariae in human blood samples. Experimental parasitology. 2009;121(4):346-51. Epub 2009/01/07. doi: 10.1016/j.exppara.2008.12.012. PubMed PMID: 19124021.
- 27. Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrobial agents and chemotherapy. 2003;47(8):2418-23. Epub 2003/07/25. doi: 10.1128/aac.47.8.2418-2423.2003. PubMed PMID: 12878499; PubMed Central PMCID: PMC166057.
- 28. Mitchell CL, Topazian HM, Brazeau NF, Deutsch-Feldman M, Muwonga J, Sompwe E, et al. Household Prevalence of Plasmodium falciparum, Plasmodium vivax, and Plasmodium ovale in the Democratic Republic of the Congo, 2013-2014. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021;73(11):e3966-e9. Epub 2020/11/26. doi: 10.1093/cid/ciaa1772. PubMed PMID: 33238298; PubMed Central PMCID: PMC8664425.
- 29. Gumbo A, Topazian HM, Mwanza A, Mitchell CL, Puerto-Meredith S, Njiko R, et al. Occurrence and Distribution of Nonfalciparum Malaria Parasite Species Among Adolescents and Adults in Malawi. The Journal of infectious diseases. 2022;225(2):257-68. Epub 2021/07/11. doi: 10.1093/infdis/jiab353. PubMed PMID: 34244739; PubMed Central PMCID: PMC8763954.
- 30. Otambo WO, Omondi CJ, Ochwedo KO, Onyango PO, Atieli H, Lee MC, et al. Risk associations of submicroscopic malaria infection in lakeshore, plateau and highland areas of Kisumu County in western Kenya. PloS one. 2022;17(5):e0268463. Epub 2022/05/17. doi: 10.1371/journal.pone.0268463. PubMed PMID: 35576208; PubMed Central PMCID: PMC9109926.
- 31. Gul D, Rodríguez-Rodríguez D, Nate E, Auwan A, Salib M, Lorry L, et al. Investigating differences in village-level heterogeneity of malaria infection and household risk factors in Papua New Guinea. Scientific reports. 2021;11(1):16540. Epub 2021/08/18. doi: 10.1038/s41598-021-95959-8. PubMed PMID: 34400687; PubMed Central PMCID: PMC8367982.
- 32. Mueller I, Widmer S, Michel D, Maraga S, McNamara DT, Kiniboro B, et al. High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malaria journal. 2009;8:41. Epub 2009/03/17. doi:

- 10.1186/1475-2875-8-41. PubMed PMID: 19284594; PubMed Central PMCID: PMC2657150.
- 33. Chen J, Wang FK, He ZX, Bai Y. Progress in the Study of Epidemiologic Characteristics and Influencing Factors of Asymptomatic Malaria Infection in Africa. Alternative therapies in health and medicine. 2021;27(6):52-6. Epub 2021/02/24. PubMed PMID: 33620333.
- 34. AM Charts. . Available from: Pixel Map Generator [\(https://pixelmap.amcharts.com/\)](https://pixelmap.amcharts.com/).
- 35. Rapp T, Amagai K, Sinai C, Basham C, Loya M, Ngasala S, et al. Micro- heterogeneity of transmission shapes the submicroscopic malaria reservoir in coastal Tanzania. medRxiv : the preprint server for health sciences. 2023. Epub 2023/09/21. doi: 10.1101/2023.09.06.23295089. PubMed PMID: 37732257; PubMed Central PMCID: PMC10508794.
- 36. Tarimo BB, Nyasembe VO, Ngasala B, Basham C, Rutagi IJ, Muller M, et al. Seasonality and transmissibility of Plasmodium ovale in Bagamoyo District, Tanzania. Parasites & vectors. 2022;15(1):56. Epub 2022/02/16. doi: 10.1186/s13071-022-05181-2. PubMed PMID: 35164867; PubMed Central PMCID: PMC8842944.
- 37. Akala HM, Watson OJ, Mitei KK, Juma DW, Verity R, Ingasia LA, et al. Plasmodium interspecies interactions during a period of increasing prevalence of Plasmodium ovale in symptomatic individuals seeking treatment: an observational study. The Lancet Microbe. 2021;2(4):e141-e50. Epub 2022/05/12. doi: 10.1016/s2666-5247(21)00009-4. PubMed PMID: 35544189; PubMed Central PMCID: PMCPMC7613221.
- 38. Ehiem RC, Lawson BWL, Larbi JA. Malaria Knowledge-Base and Prevalence of Parasitaemia in Asymptomatic Adults in the Forest Zone of Ghana. Acta parasitologica. 2022;67(4):1719-31. Epub 2022/10/20. doi: 10.1007/s11686-022- 00629-y. PubMed PMID: 36261782.
- 39. Le Goff M, Kendjo E, Thellier M, Piarroux R, Boelle PY, Jauréguiberry S. Impact of Chemoprophylaxis on Plasmodium vivax and Plasmodium ovale Infection Among Civilian Travelers: A Nested Case-Control Study With a Counterfactual Approach on 862 Patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023;76(3):e884-e93. Epub 2022/08/14. doi: 10.1093/cid/ciac641. PubMed PMID: 35962785.
- 40. Holzschuh A, Gruenberg M, Hofmann NE, Wampfler R, Kiniboro B, Robinson LJ, et al. Co-infection of the four major Plasmodium species: Effects on densities and gametocyte carriage. PLoS neglected tropical diseases. 2022;16(9):e0010760. Epub 2022/09/14. doi: 10.1371/journal.pntd.0010760. PubMed PMID: 36099312;

PubMed Central PMCID: PMC9506632.

 41. Zhang M, Wang C, Otto TD, Oberstaller J, Liao X, Adapa SR, et al. Uncovering the essential genes of the human malaria parasite Plasmodium falciparum by saturation mutagenesis. Science (New York, NY). 2018;360(6388). Epub 2018/05/05. doi: 10.1126/science.aap7847. PubMed PMID: 29724925; PubMed Central PMCID: PMC6360947.

 42. Prieur E, Druilhe P. The malaria candidate vaccine liver stage antigen-3 is highly conserved in Plasmodium falciparum isolates from diverse geographical areas. Malaria journal. 2009;8:247. Epub 2009/10/31. doi: 10.1186/1475-2875-8-247. PubMed PMID: 19874576; PubMed Central PMCID: PMC2774867.

 43. Perlaza BL, Valencia AZ, Zapata C, Castellanos A, Sauzet JP, Blanc C, et al. Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver-stage antigen-3-derived long synthetic peptides. European journal of immunology. 2008;38(9):2610-5. Epub 2008/09/16. doi: 10.1002/eji.200738055. PubMed PMID: 18792413.

- 44. Brahimi K, Badell E, Sauzet JP, BenMohamed L, Daubersies P, Guérin-Marchand C, et al. Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo. Infection and immunity. 2001;69(6):3845- 52. Epub 2001/05/12. doi: 10.1128/iai.69.6.3845-3952.2001. PubMed PMID: 11349050; PubMed Central PMCID: PMC98406.
- 45. Nishimoto Y, Arisue N, Kawai S, Escalante AA, Horii T, Tanabe K, et al. Evolution and phylogeny of the heterogeneous cytosolic SSU rRNA genes in the genus Plasmodium. Molecular phylogenetics and evolution. 2008;47(1):45-53. Epub 2008/03/13. doi: 10.1016/j.ympev.2008.01.031. PubMed PMID: 18334303.
- 46. Lloyd YM, Esemu LF, Antallan J, Thomas B, Tassi Yunga S, Obase B, et al. PCR- based detection of Plasmodium falciparum in saliva using mitochondrial cox3 and varATS primers. Tropical medicine and health. 2018;46:22. Epub 2018/07/07. doi: 10.1186/s41182-018-0100-2. PubMed PMID: 29977122; PubMed Central PMCID: PMC6013985.
- 47. Nundu SS, Culleton R, Simpson SV, Arima H, Muyembe JJ, Mita T, et al. Malaria parasite species composition of Plasmodium infections among asymptomatic and symptomatic school-age children in rural and urban areas of Kinshasa, Democratic Republic of Congo. Malaria journal. 2021;20(1):389. Epub 2021/10/04. doi: 10.1186/s12936-021-03919-4. PubMed PMID: 34600558; PubMed Central PMCID: PMC8487491.
- 48. Hershey CL, Florey LS, Ali D, Bennett A, Luhanga M, Mathanga DP, et al. Malaria Control Interventions Contributed to Declines in Malaria Parasitemia, Severe

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.31.23297819;](https://doi.org/10.1101/2023.10.31.23297819) this version posted October 31, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted

![](_page_28_Picture_186.jpeg)

![](_page_28_Picture_187.jpeg)

 Plasmodium falciparum is evolving to escape malaria rapid diagnostic tests in Ethiopia. Nature microbiology. 2021;6(10):1289-99. Epub 2021/09/29. doi: 10.1038/s41564-021-00962-4. PubMed PMID: 34580442; PubMed Central PMCID: PMC8478644.

 53. Ripa T, Nilsson P. A variant of Chlamydia trachomatis with deletion in cryptic plasmid: implications for use of PCR diagnostic tests. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2006;11(11):E061109.2. Epub 2007/01/11. doi: 10.2807/esw.11.45.03076- en. PubMed PMID: 17213548.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.31.23297819;](https://doi.org/10.1101/2023.10.31.23297819) this version posted October 31, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a CC-BY 4.0 International license.

# **Supporting information**

- **S1 Table. Candidate primer and probe sets evaluated for the detection of** *P. ovale*
- *curtisi* **and** *P. ovale wallikeri.*
- **S2 Table. Limit of detection of the optimized, duplex** *P. ovale curtisi* **and** *P. ovale*
- *wallikeri* **assay versus serially diluted plasmid DNA.**
- **S1 Fig. 95% lower limits of detection determined using probit analysis.** A) *P. ovale*
- *curtisi* 95% lower limits of detection (4.2 parasites/µl [95% CI 3.1-9.5]). B) *P. ovale*
- *wallikeri* 95% lower limits of detection (41.2 parasites/µl [95% CI 33.3-58.3]).
- Confidence intervals are shown in lighter shade.

![](_page_30_Figure_0.jpeg)

Figure 1

 $(a)$ 

![](_page_31_Figure_1.jpeg)

![](_page_31_Picture_32.jpeg)

 $(b)$ 

Figure 2

![](_page_32_Figure_0.jpeg)

Figure 3

P. ovale (n)

![](_page_33_Picture_8.jpeg)

# Figure 4